3,5,6,7,8,3',4'-HEPTAMETHOXYFLAVONE


Synonyms	3,5,6,7,8,3',4'-Heptamethoxy-Flavone 3,5,6,7,8,3',4'-Heptamethoxyflavone
UNII	288R4CAV1V
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	SSXJHQZOHUYEGD-UHFFFAOYSA-N
Smiles	COC1=C(Oc2c(OC)c(OC)c(OC)c(OC)c2C1=O)c3ccc(OC)c(OC)c3
InChI	InChI=1S/C22H24O9/c1-24-12-9-8-11(10-13(12)25-2)16-19(27-4)15(23)14-17(26-3)20(28-5)22(30-7)21(29-6)18(14)31-16/h8-10H,1-7H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H24O9
Molecular Weight	432.42
AlogP	2.73
Hydrogen Bond Acceptor	9.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	8.0
Polar Surface Area	90.91
Molecular species	None
Aromatic Rings	2.0
Heavy Atoms	31.0

Assay Description	Organism	Bioactivity
Induction of resistance against Phytophthora citrophthora in Citrus (tangelo Nova) fruits assessed as increase of polymethoxyflavones levels at 20 to 250 ppm up to 160 days	Citrus	43.0 %
Induction of resistance against Phytophthora citrophthora in Citrus (tangelo Nova) fruits assessed as increase of polymethoxyflavones levels at 20 to 250 ppm after 7 days	Citrus	29.0 %
Antifungal activity against Phytophthora citrophthora assessed as inhibition of radical growth at 0.1 to 1 g/L up to 200 hr	Phytophthora citrophthora	None
Antifungal activity against Phytophthora citrophthora after 100 hr	Phytophthora citrophthora	1040000.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL77993
FDA SRS	288R4CAV1V
PubChem	150893
SureChEMBL	SCHEMBL1764676

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).